User profiles for Carla Coffin

carla coffin

Professor of Medicine
Verified email at ucalgary.ca
Cited by 5270

New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection

CS Coffin, K Zhou, NA Terrault - Gastroenterology, 2019 - Elsevier
Tests to detect the presence and activity of hepatitis B virus (HBV) are the cornerstones of
diagnosis and management. Assays that detect or measure serum levels of HB surface antigen…

[HTML][HTML] Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma

S D'souza, KCK Lau, CS Coffin… - World journal of …, 2020 - ncbi.nlm.nih.gov
Chronic infection with viral hepatitis affects half a billion individuals worldwide and can lead
to cirrhosis, cancer, and liver failure. Liver cancer is the third leading cause of cancer-…

[PDF][PDF] Hepatitis B and pregnancy: virologic and immunologic characteristics

SS Joshi, CS Coffin - Hepatology communications, 2020 - Wiley Online Library
The hepatitis B virus (HBV) is an important human pathogen. Unvaccinated infants infected
through mother‐to‐child transmission (MTCT) are at >95% risk of developing serum hepatitis …

A population-based study of pyogenic liver abscesses in the United States: incidence, mortality, and temporal trends

…, KB Laupland, E Dixon, C Coffin… - Official journal of the …, 2010 - journals.lww.com
OBJECTIVES: Few population-based studies have evaluated pyogenic liver abscess (PLA)
in North America. We assessed the incidence of PLA and evaluated predictors of mortality. …

The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection

…, JG McHutchison, S Kottilil, B Freilich, CS Coffin… - Journal of …, 2015 - Elsevier
Background & Aims GS-9620 is an oral agonist of toll-like receptor 7, a pattern-recognition
receptor whose activation results in innate and adaptive immune stimulation. We evaluated …

Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

…, V Chulanov, L Cisneros, C Coffin… - The Lancet …, 2023 - thelancet.com
Background The 2016 World Health Assembly endorsed the elimination of hepatitis B virus (HBV)
infection as a public health threat by 2030; existing therapies and prophylaxis …

Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy

…, SS Lee, SJ Urbanski, AI Aspinall, CS Coffin… - Canadian Journal of …, 2013 - hindawi.com
BACKGROUND: Although most patients with autoimmune hepatitis (AIH) respond to treatment
with prednisone and/or azathioprine, some patients are intolerant or refractory to standard …

[HTML][HTML] Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease

…, J Tracey, F Pradhan, AAM Shaheen, CS Coffin… - PloS one, 2014 - journals.plos.org
Background Liver stiffness measurement (LSM) by transient elastography (TE, FibroScan) is
a validated method for noninvasively staging liver fibrosis. Most hepatic complications occur …

Hydrogen sulphide synthesis in the rat and mouse gastrointestinal tract

GR Martin, GW McKnight, MS Dicay, CS Coffin… - Digestive and Liver …, 2010 - Elsevier
AIMS: Hydrogen sulphide (H 2 S) exerts several anti-inflammatory effects, accelerates the
healing of experimental gastric ulcers, and can stimulate intestinal secretion. Little is known …

Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)

…, SH Ahn, TT Chang, CY Peng, D Wong, CS Coffin… - Journal of …, 2016 - Elsevier
Background & Aims Peginterferon lambda-1a (lambda) is a Type-III interferon, which, like
alfa interferons, has antiviral activity in vitro against hepatitis B virus (HBV) and hepatitis C …